Clinical trial · Observational
Cytokine Gene Polymorphisms in Bone Marrow Failure
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will examine whether cytokine gene polymorphisms affect the progression or response to therapy of bone marrow failure disorders. Cytokine genes instruct cells to produce proteins called cytokines that influence immune system response. As with many genes, the cytokine genes differ slightly from person to person. These differences are called gene polymorphisms. Different patients with the same bone marrow failure disease often progress and respond to treatment differently. This study will look at the possible role of cytokine gene polymorphisms in these differences. Patients between 2 and 80 years old who have participated in an NHLBI Hematology Branch treatment protocol for acquired aplastic anemia, myelodysplastic syndrome, or pure red cell aplasia are recruited to participate in this study. Blood collected and stored at the time of screening for the treatment protocol will be tested for cytokine gene polymorphisms. No additional tests, procedures, or treatments are involved in this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Diseases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- Bone marrow failure subjects
Primary outcomes (1)
- measure
- To define the variability that exists in cytokine genes from bone marrow failure patients by typing their DNA for polymorphisms.
- timeFrame
- Ongoing
- description
- Ongoing
Secondary outcomes (1)
- measure
- Compare cytokine polymorphisms of normal individuals (public domain studies and 03-H-0121) to those of patients with known bone marrow failure.Correlate cytokine gene polymorphisms of aplastic anemia and other bone marrow failure syndrome patien...
- timeFrame
- Ongoing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 80 Years
Show eligibility criteria text
* INCLUSION CRITERIA: Participation on a Hematology Branch bone marrow failure treatment protocol. Diagnosis with one of the following bone marrow failure conditions: Acquired aplastic anemia Myelodysplastic syndrome (MDS) Pure red cell aplasia (PRCA) For adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian. Informed assent from minors: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend. Age greater than or equal to 2 and less than or equal to 80. EXCLUSION CRITERIA: Subjects unable to comprehend the investigational nature of the laboratory research.
References
Publications (0)
Data not yet available